Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. - Wikidata - wikimedia - TriplyDB

Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.

Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.

http://www.wikidata.org/entity/Q34354995

about

Broad-Spectrum Drugs Against Viral Agents FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling.Expression of toll-like receptors in genital tract tissues from normal and HIV-infected men NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.RNA-dependent protein kinase is required for alpha-1 interferon transgene-induced resistance to genital herpes simplex virus type 2.The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques.CpG oligodeoxynucleotides improve the survival of pregnant and fetal mice following Listeria monocytogenes infection.Commensal bacteria modulate innate immune responses of vaginal epithelial cell multilayer cultures Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection.Effects of particle size on toll-like receptor 9-mediated cytokine profiles.Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODN-based vaginal microbicide Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection.Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.Innate and adaptive immune responses to herpes simplex virus Evasion of early antiviral responses by herpes simplex viruses.CpG DNA: trigger of sepsis, mediator of protection, or both?A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge Tweaking Innate Immunity: the Promise of Innate Immunologicals As Anti-infectives Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia Antiinfective applications of toll-like receptor 9 agonists.Salmonella enterica serovar typhimurium exploits Toll-like receptor signaling during the host-pathogen interaction.FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection.Toll-like receptors and genital tract infection.Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options.An early event in the herpes simplex virus type-2 replication cycle is sufficient to induce Chlamydia trachomatis persistence.Sensing herpes: more than toll.Prophylactic and therapeutic implications of toll-like receptor ligands.Immunotherapeutic potential of CpG oligodeoxynucleotides in veterinary species.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens.Contribution of nitric oxide to CpG-mediated protection against Listeria monocytogenes.Effect of pretreatment with toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis.Vaginal Mucosa and Drug Delivery

P2860

Q27487859-1D3A4EC4-51BA-496F-B5D2-6F82DA2F3297 Q33389846-ADA53094-84C5-4C89-A061-885B54D695BE Q33596477-17C2F9E5-E633-41D6-970E-A083692E8A65 Q33707533-4BEBF899-0321-465C-B8B1-61168F376892 Q33710019-1B10ADA9-4C1F-493E-A680-4926A0E15797 Q33725145-54BA465A-52D7-4CFF-8278-C9DBAB092BBF Q33883922-EE8BCFA3-9685-40D2-B6BC-C71D72D00644 Q34124090-DC7DDFA3-7852-4D8C-A343-8F112871FE10 Q34145320-63AA25BF-A726-4577-BD55-005E199CD399 Q34193360-5A4D2300-9FF7-4B02-930C-7A1284B451B3 Q34350019-F3595B8F-FACF-4AF1-A1FA-EA7F0E15D7FE Q34529742-1F5E2780-832C-4F1A-B82B-DA70A2F187FD Q34540279-35A4393D-D5A2-4E65-B3E8-18BCD597123B Q34648207-7B6D9924-A5C1-4C7A-ACDF-5EAF69F7BF3C Q34830678-4E0E6A28-5B97-4C04-90F4-CA7C3D0061AA Q35101507-91074A51-57D5-4B13-AB39-E2287F098CC6 Q35101552-C6841D35-BF2B-4F52-A2DA-D1D82877E586 Q35182216-AFB214B7-673B-4687-A952-DE67E54F77C0 Q35260078-351136D8-A72B-4BA8-9C05-50AB3B026E72 Q35414669-317E78FA-E3C8-40F1-8DD5-D77A555C9FD5 Q35585084-AE70F737-E12C-4C3B-8ABE-4F196A32709B Q35871689-BF64199E-C3B7-485D-842E-093F86994AAE Q36171257-081F93BD-09FE-40DF-9E9A-EFA9001A68B2 Q36525130-547E4BCB-6F91-4493-92F3-7D7A2103DD69 Q36868322-E81776A3-3016-458F-B577-5B27872922E2 Q37410335-071A3791-9524-426C-8A91-813395749109 Q37428262-6C96FD8A-9C01-45FA-81E7-ED72BAE068B5 Q37705702-FB89DF0C-4097-46EA-B9EF-E21FA72897FE Q37771396-126A8FA6-CDCB-4A64-8F6A-DB7319EC8B9D Q37860814-EA32FACF-4DD8-4726-8562-F11F75C1F69C Q37948677-FE1AA4A6-24D8-406E-9F88-D3763BDCC1D4 Q37989884-A0A5C765-12A7-47B3-A951-5BFB2F682B66 Q38131836-96412ED7-9C76-41E2-AF95-736C4B4DD717 Q38212516-4FA349C2-5257-492A-9F84-1C08B33F4BAC Q40327930-D134E107-EC6B-413E-A5C2-D28EA8C808E3 Q42151564-1B6FB55B-9AA2-4E9C-B1C8-E79E6EA771F3 Q45392569-86435A6C-7DC8-45CC-9534-07E8FE862C01 Q57570821-0B0BD417-6084-4D68-9249-5AFF34822D35

P2860

Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.

http://www.wikidata.org/entity/Q34354995

description

2002 nî lūn-bûn

@nan

2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Use of immunostimulatory seque ...... implex virus type 2 infection.

@ast

Use of immunostimulatory seque ...... implex virus type 2 infection.

@en

Use of immunostimulatory seque ...... implex virus type 2 infection.

@nl

type

label

Use of immunostimulatory seque ...... implex virus type 2 infection.

@ast

Use of immunostimulatory seque ...... implex virus type 2 infection.

@en

Use of immunostimulatory seque ...... implex virus type 2 infection.

@nl

prefLabel

Use of immunostimulatory seque ...... implex virus type 2 infection.

@ast

Use of immunostimulatory seque ...... implex virus type 2 infection.

@en

Use of immunostimulatory seque ...... implex virus type 2 infection.

@nl

P1433

Q34354995-89C03D77-AD07-49DF-BF2C-0F269A5F0EBE

P1476

Q34354995-5D40D346-8D36-4FDC-AE83-8EA576FF06E2

P2093

Q34354995-055A5293-7C62-4DC1-B1A7-F29625D1A5AC

Q34354995-2B1E5566-8DA2-4D5E-A46E-4448DB5EF889

Q34354995-748EB70F-C67D-4B68-ADBF-3792138D99E7

Q34354995-8771C215-9234-43D2-9F83-BCF6E496630A

Q34354995-907A1F53-E18E-43A9-A31B-CE28E6EA545C

Q34354995-ADB3BB28-622D-40B3-B408-784A8751691B

Q34354995-BA2E7455-CD4C-4906-A480-BF5C1D91812D

Q34354995-FC4489FC-925F-4882-879F-FEF766A9A399

P2860

Q34354995-0B69DE85-B69D-40DF-B116-6C2E85C3A827

Q34354995-0C0EBFCE-2EE4-4BF3-8599-20E98969A65D

Q34354995-1BC41D0E-BEA7-4053-87D5-BE8A8DAFE15A

Q34354995-1D6F9871-3F18-4C82-B985-72C9F5D6AFB3

Q34354995-1ED9A456-711E-4834-B7A9-E05A397F7BC1

Q34354995-203BEE02-6694-4CB9-B908-A523375337C3

Q34354995-240F0EA1-425F-4840-BC9C-C4B0B51A4B1F

Q34354995-28AE55E7-F1E7-4EBB-B73B-A085E34DC9F0

Q34354995-2AD70FD5-2524-47A7-B3C8-7CA9CCD2FCB5

Q34354995-2B7D6AAA-9450-4F92-A550-B5748FBFA8F6

P304

Q34354995-03F48680-861E-4219-AB10-2A6AAC29D197

P31

Q34354995-5117B0CA-07EC-4AB7-BC3C-FE74E99891BE

P356

Q34354995-7E417DCA-5E67-44D1-AFFA-83A90D73F802

P407

Q34354995-F2C8A5AE-E521-453B-B1D5-C50C14872FCD

P433

Q34354995-83425831-C50C-4E37-91FA-E71A320AF007

P478

Q34354995-2E8A149F-DA34-48E8-98B0-EF05884DC7EE

P577

Q34354995-BBB9B01A-8CE2-4E4F-8AA1-35FF1D1F0C61

P5875

Q34354995-F1DFD35B-D70E-4B8E-B37B-217303117A6B

P698

Q34354995-6A47C314-A3E5-4668-A8A1-2B1D689DB5C0

P921

Q34354995-609E5A39-DF96-4CEC-9360-A64F841BC904

P932

Q34354995-D2231533-8C42-421F-AFC1-19EA2A58B57B

P356

JVI.76.22.11387-11396.2002

P1433

Journal of Virology

P1476

Use of immunostimulatory seque ...... implex virus type 2 infection.

@en

P2093

Anthony Zalar

http://www.w3.org/2001/XMLSchema#string

Carrie Brown

http://www.w3.org/2001/XMLSchema#string

Claudia Chalk

http://www.w3.org/2001/XMLSchema#string

Debbie Higgins

http://www.w3.org/2001/XMLSchema#string

Gary Van Nest

http://www.w3.org/2001/XMLSchema#string

Joseph Eiden

http://www.w3.org/2001/XMLSchema#string

Lawrence R Stanberry

http://www.w3.org/2001/XMLSchema#string

Richard B Pyles

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Condoms on Reducing the Transmission of Herpes Simplex Virus Type 2 From Men to Women

Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine.

Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.

Herpes simplex virus latency and nucleoside analogues.

An important role for major histocompatibility complex class I-restricted T cells, and a limited role for gamma interferon, in protection of mice against lethal herpes simplex virus infection.

Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates

CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.

Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity.

Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons.

Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmission

P304

11387-11396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.76.22.11387-11396.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6119855

http://www.w3.org/2001/XMLSchema#string

P698

12388699

http://www.w3.org/2001/XMLSchema#string

P921

sexual transmission

P932

136753

http://www.w3.org/2001/XMLSchema#string